Empirical Financial Services LLC d.b.a. Empirical Wealth Management Takes Position in PTC Therapeutics, Inc. $PTCT

Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 20,775 shares of the biopharmaceutical company’s stock, valued at approximately $1,275,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Hood River Capital Management LLC increased its stake in PTC Therapeutics by 654.4% during the second quarter. Hood River Capital Management LLC now owns 636,502 shares of the biopharmaceutical company’s stock worth $31,087,000 after acquiring an additional 552,130 shares during the last quarter. State Street Corp grew its holdings in shares of PTC Therapeutics by 22.1% during the 2nd quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company’s stock worth $146,347,000 after purchasing an additional 541,558 shares during the period. Man Group plc increased its position in PTC Therapeutics by 157.4% during the 2nd quarter. Man Group plc now owns 671,513 shares of the biopharmaceutical company’s stock worth $32,797,000 after purchasing an additional 410,653 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new position in PTC Therapeutics in the second quarter valued at approximately $10,153,000. Finally, Squarepoint Ops LLC lifted its position in PTC Therapeutics by 1,603.8% during the second quarter. Squarepoint Ops LLC now owns 181,978 shares of the biopharmaceutical company’s stock valued at $8,888,000 after buying an additional 171,297 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on PTCT shares. Jefferies Financial Group increased their price objective on shares of PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Bank of America lowered their price target on PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating for the company in a report on Friday. Wells Fargo & Company cut their price objective on PTC Therapeutics from $93.00 to $86.00 and set an “overweight” rating on the stock in a research report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of PTC Therapeutics in a research report on Friday. Finally, Wall Street Zen downgraded PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Ten equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $80.73.

Insider Buying and Selling

In other news, CEO Matthew B. Klein sold 8,089 shares of the stock in a transaction that occurred on Tuesday, December 30th. The stock was sold at an average price of $76.64, for a total transaction of $619,940.96. Following the completion of the transaction, the chief executive officer directly owned 341,875 shares in the company, valued at approximately $26,201,300. This represents a 2.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Allan Steven Jacobson sold 14,199 shares of PTC Therapeutics stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $83.55, for a total transaction of $1,186,326.45. Following the completion of the sale, the director owned 17,451 shares of the company’s stock, valued at approximately $1,458,031.05. This trade represents a 44.86% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 250,873 shares of company stock worth $19,595,975 over the last 90 days. 5.50% of the stock is currently owned by corporate insiders.

Key Headlines Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a “buy” rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
• Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
• Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
• Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
• Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

PTC Therapeutics Price Performance

Shares of PTC Therapeutics stock opened at $70.66 on Monday. PTC Therapeutics, Inc. has a 1-year low of $35.95 and a 1-year high of $87.50. The company has a market capitalization of $5.85 billion, a PE ratio of 9.13 and a beta of 0.48. The business has a 50-day moving average of $74.91 and a 200-day moving average of $68.14.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.46). The business had revenue of $164.68 million during the quarter, compared to analyst estimates of $281.45 million. PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.The company’s revenue was down 22.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.85) EPS. On average, equities analysts expect that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

PTC Therapeutics Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.